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ABSTRACT 
Tumour necrosis factor-a (TNFa) is a pleiotropic cytokine that plays a critical role in 
cellular response to virus infection. Virtually all poxviruses encode genes that are 
homologous to human tumour necrosis factor receptors (TNFRs). The viral "T2" TNFR 
proteins are well characterized from Leporipox viruses, myxoma (Myx) and shape 
fibroma virus. MyxT2 has previously been shown to bind to and inhibit rabbit TN Fa in 
a species-specific manner and, more recently, has been shown to bind to human 
cellular TNFRs and inhibit TNFR1-induced cell death in a non species-specific manner. 
In contrast, the human-tropic Orthopoxviruses TNFR proteins have been poorly 
characterised, since variola virus (VAR) existed before molecular virology capabilities 
and the monkeypox virus (MPV) is restricted for research . This study sought to 
characterize the TNFR proteins, VARG4R and MPVJ2R, encoded by strict species -
specific variola virus and the broad host range monkeypox virus, and compare them to 
the well characterized MyxT2 protein . 
W ith WHO Smallpox Com mittee approval, codon opt imised cDNAs for VARG4R and 
MPVJ2R were constructed and these proteins were expressed as ( -terminal myc-His-
tagged fusion proteins by transient t ransfection in HEK293T cells . Both VARG4R and 
MPVJ2R are expressed and detectable in cell lysates and culture supernatants, exactly 
as occurs for MyxT2. However, w hile MyxT2 is both a dimer and a monomer, VARG4R 
is predominant ly a dimer and MPVJ2R is exclusively a monomer. Secreted VARG4R 
and MPVJ2R are heavily glycosylated consistent with their numerous N-linked 
glycosylation sites. In TNFa neutral izat ion L929 cytotoxic ity assays, VARG4R inhibits 
rabbit, mouse, human and rhesus macaque TNFa. Although monkeypox virus has an 
extremely broad host range, surprisingly MPVJ2R has no TNFa inhibitory activity 
against rabbit, human, or rhesus macaque TNFa. Consistent with MyxT2, VARG4R and 
MPVJ2R inhibit TNFR1-induced cell death. It has previously been demonstrated that 
the viral pre-ligand association domain (PLAD) is essential for MyxT2 inhibition of 
TNFRl-induced cell death. Interestingly, MyxT2 PLAD, VARG4R PLAD and MPVJ2R 
xviii 
PLAD proteins also inhibit TNFRl-induced cell death, confirming the critical role of the 
viral PLAD domain in the function of these viral TN FR proteins. 
Collectively these data suggest that, like MyxT2, secreted VARG4R protein acts as a 
functional TNFa-inhibitory factor during variola infection, but poxviruses with a broad 
host range, such as monkeypox, use other non species-specific mechanisms for host 
immune evasion. Overall, this study expands on our limited knowledge of variola and 
monkeypox viruses' mechanisms of immune evasion and further confirms the pivotal 
role of the viral PLAD in viral inhibition of TN Fa-TN FR signaling. 
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